Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous CD8+ melanoma-specific T cells
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD8+ melanoma-specific T cells are an investigational adoptive cell therapy developed by the M.D. Anderson Cancer Center for the treatment of metastatic melanoma. This personalized immunotherapy involves isolating a patient's own CD8+ T lymphocytes, which are then expanded and selected ex vivo for their specificity against melanoma-associated antigens. Once re-infused into the patient, these T cells are intended to recognize and directly eliminate tumor cells. In clinical protocols, this cell therapy is typically administered following lymphodepleting chemotherapy (such as cyclophosphamide) and is often combined with immune-stimulating agents like aldesleukin (interleukin-2) and checkpoint inhibitors such as ipilimumab to enhance the expansion, persistence, and anti-tumor efficacy of the infused cells.
- Other names
- Autologous CD8+ antigen-specific T cellsCellular Adoptive Immunotherapy
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on Autologous CD8+ melanoma-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous CD8+ melanoma-specific T cells.